Miglustat (Synonyms: N-Butyldeoxynojirimycin; NB-DNJ; OGT 918)

Name: Miglustat
Brand: MedChemExpress
SKU: HY-17020
Rating: 5.0 (6 reviews)

Cat. No.: HY-17020 Purity: 99.95%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease.

For research use only. We do not sell to patients.

CAS No. : 72599-27-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in Water	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Miglustat:

6 Publications Citing Use of MCE Miglustat

In Vivo Imaging

Cell Proliferation/Viability Assay

RT-PCR

Cell Imaging/Staining

: Miglustat purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]; Miglustat (5, 10 μM; 24 h) showed no cytotoxicity for Vero cells.

: Miglustat purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]; Miglustat (5, 10 μM) decreased the PEDV N mRNA levels in a dose-dependent manner in Vero cells.

: Miglustat purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]; Miglustat (5, 10 μM) decreased the PEDV N prodein levels in a dose-dependent manner in Vero cells.

: Miglustat purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Mar 18;99(3):e0001825. [Abstract]; Immunofluorescence assay (IFA) images of Vero cells infected with PEDV and treated with indicated Miglustat (5, 10 μM). Viral N-protein is shown in green, and the nuclei are blue.

: Miglustat purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 14;15(1):6970. [Abstract]; Miglustat combined with anti-PD-1 promotes tumour inhibition. MC38-OVA cells (1 × 105 328 ) were subcutaneously injected into C57BL/6 mice treated with PBS, Miglustat alone (10 mg/kg), anti-PD-1 antibody alone (200 mg/kg per mouse) or Miglustat plus anti-PD-1 as indicated and tumour formation was observed. Tumour sizes were measured every 3 days. The average and individual tumour curves are shown.

: Miglustat purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]; Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks. NB-DNJ is a drug to disrupt the fusion of the small proacrosomal vesicles into a single acrosome. PNA-FITC-labeled acrosome and EGFP signals were almost lost after NB-DNJ treatment.

: Miglustat purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]; Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks, the shape of sperm from Ccin-eGFP-KI mice was obviously changed and the acrosome was absent.

: Miglustat purchased from MedChemExpress. Usage Cited in: Cell Rep. 2022 Jul 5;40(1):111049. [Abstract]; Ccin-EGFP-KI male mice were fed by 15 mg/kg Miglustat (NB-DNJ) per day for 5 weeks, The protein levels of Zpbp1 (an acrosomal marker) and eGFP-tagged calicin were significantly reduced.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Miglustat (N-Butyldeoxynojirimycin) is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat can be used for the research of type I gaucher disease^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
CuFi-1	IC₅₀	2 μM Compound: 1; D-NBDNJ	Anti-inflammatory activity in human CuFi1 cells assessed as reduction in Pseudomonas aeruginosa PAO1-induced IL-8 mRNA expression level pretreated for 1 hr followed by Pseudomonas aeruginosa PAO1 challenge and measured after 4 hrs by RT-PCR analysis Anti-inflammatory activity in human CuFi1 cells assessed as reduction in Pseudomonas aeruginosa PAO1-induced IL-8 mRNA expression level pretreated for 1 hr followed by Pseudomonas aeruginosa PAO1 challenge and measured after 4 hrs by RT-PCR analysis	[PMID: 31075609]
MOLT-4	CC₅₀	> 100 mg/mL Compound: 3	Concentration giving 50% inhibition of growth of mock-infected MOLT-4 cells Concentration giving 50% inhibition of growth of mock-infected MOLT-4 cells	[PMID: 7608901]
MOLT-4	EC₅₀	37 mg/mL Compound: 3	Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MOLT-4 cells Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MOLT-4 cells	[PMID: 7608901]
MT4	CC₅₀	> 100 mg/mL Compound: 3	Concentration giving 50% inhibition of growth of mock-infected MT-4 cells Concentration giving 50% inhibition of growth of mock-infected MT-4 cells	[PMID: 7608901]
MT4	EC₅₀	49 mg/mL Compound: 3	Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MT-4 cells Concentration giving 50% inhibition of HIV-1 induced cytopathogenicity in MT-4 cells	[PMID: 7608901]
RAW	IC₅₀	50 μM Compound: 1	Inhibition of glucosylceramide synthase in mouse RAW cells preincubated with compound for 15 mins by in-situ enzyme inhibition assay Inhibition of glucosylceramide synthase in mouse RAW cells preincubated with compound for 15 mins by in-situ enzyme inhibition assay	[PMID: 24900289]
RAW	IC₅₀	50 μM Compound: 1, Zavesca	Inhibition of glucosylceramide synthase in mouse RAW cells preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence scanner Inhibition of glucosylceramide synthase in mouse RAW cells preincubated for 15 mins followed by substrate addition and measured after 1 hr by fluorescence scanner	[PMID: 24900342]
SH-SY5Y	IC₅₀	0.014 μM Compound: 1; D-NBDNJ	Inhibition of NLGase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of AMP-DNM by fluorescence based assay Inhibition of NLGase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of AMP-DNM by fluorescence based assay	[PMID: 31075609]
SH-SY5Y	IC₅₀	118 μM Compound: 1; D-NBDNJ	Inhibition of GCase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of conduritol B epoxide by fluorescence based assay Inhibition of GCase in human SH-SY5Y cells using MUG-Gluc as fluorogenic substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of conduritol B epoxide by fluorescence based assay	[PMID: 31075609]

In Vitro

Miglustat (200 μM; 2, 4 and 24 h) restores F508del-CFTR (cystic fibrosis transmembrane conductance regulator) function in cystic fibrosis (CF) bronchial epithelial IB3-1 and CuFi-1 cells. Miglustat reduces the inflammatory response to P. aeruginosa in both CF and non-CF bronchial cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Miglustat (0.2 mg/kg; oral administration; once) is able to rescue synaptic plasticity deficits, to restore ERKs activation and to counteract hyperexcitability^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NPC1−/− mice^[1]
Dosage:	0.2 mg/kg
Administration:	Oral administration; once
Result:	Was able to rescue synaptic plasticity deficits, to restore ERKs activation and to counteract hyperexcitability.

Clinical Trial

Molecular Weight

219.28

Formula

C₁₀H₂₁NO₄

CAS No.

72599-27-0

Appearance

Solid

Color

White to off-white

SMILES

O[C@H]1[C@H](O)[C@@H](CO)N(CCCC)C[C@@H]1O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

Solvent & Solubility

In Vitro:

H₂O : 175 mg/mL (798.07 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.5604 mL	22.8019 mL	45.6038 mL
5 mM	0.9121 mL	4.5604 mL	9.1208 mL
10 mM	0.4560 mL	2.2802 mL	4.5604 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.95%

Select Batch:

Data Sheet (274 KB) SDS (394 KB)

COA (249 KB) HNMR (251 KB) RP-HPLC (196 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. J Cyst Fibros. 2008 Nov;7(6):555-65. [Content Brief]

[2]. G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. Neural Plast. 2016:2016:3830424. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	4.5604 mL	22.8019 mL	45.6038 mL	114.0095 mL
	5 mM	0.9121 mL	4.5604 mL	9.1208 mL	22.8019 mL
	10 mM	0.4560 mL	2.2802 mL	4.5604 mL	11.4009 mL
	15 mM	0.3040 mL	1.5201 mL	3.0403 mL	7.6006 mL
	20 mM	0.2280 mL	1.1401 mL	2.2802 mL	5.7005 mL
	25 mM	0.1824 mL	0.9121 mL	1.8242 mL	4.5604 mL
	30 mM	0.1520 mL	0.7601 mL	1.5201 mL	3.8003 mL
	40 mM	0.1140 mL	0.5700 mL	1.1401 mL	2.8502 mL
	50 mM	0.0912 mL	0.4560 mL	0.9121 mL	2.2802 mL
	60 mM	0.0760 mL	0.3800 mL	0.7601 mL	1.9002 mL
	80 mM	0.0570 mL	0.2850 mL	0.5700 mL	1.4251 mL
	100 mM	0.0456 mL	0.2280 mL	0.4560 mL	1.1401 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Miglustat Related Classifications

Neurological Disease Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Miglustat72599-27-0N-Butyldeoxynojirimycin NB-DNJ OGT 918OGT918OGT 918OGT-918Glucosylceramide Synthase (GCS)oralceramide glucosyltransferasetype I gaucher diseaseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Miglustat (Synonyms: N-Butyldeoxynojirimycin; NB-DNJ; OGT 918)

Customer Review

Other Forms of Miglustat:

Miglustat Related Antibodies

6 Publications Citing Use of MCE Miglustat

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Miglustat Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Miglustat Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report